Revenue growth outpaced costs, lifting Sai Life's margin to 28.30%
Consolidated net profit rose 17.27% YoY, with limited support from other income and a largely unchanged tax rate.
Filed 05 Nov 2026, 22:57 IST · after market close · Sai Life Sciences Ltd (SAILIFE)
Key takeaways
- Consolidated revenue grew 22.54% YoY, outpacing expense growth of 20.57% and lifting operating profit 27.82%.
- Operating margin expanded 1.17 percentage points YoY to 28.30%, while other income contributed only 3.02% of pre-tax profit.
- Management said it expects a stronger second half, with H1 FY27 capex at Rs 621 cr and new capacity being added.
Price around the results
Revenue growth improved operating leverage
Sai Life's consolidated revenue grew 22.54% YoY and 18.82% QoQ, while operating profit increased 27.82% and 25.93%, respectively. Expenses grew more slowly than revenue in both comparisons, rising 20.57% YoY and 16.23% QoQ. This spread drove the operating-margin expansion rather than a reduction in the absolute cost base.
Margin improved despite higher finance costs
Operating margin widened 1.17 percentage points YoY and 1.60 percentage points QoQ as revenue growth exceeded expense growth. Interest expense rose 17.01% YoY and 43.19% QoQ, which limited the conversion of operating gains into pre-tax profit. Other income accounted for only 3.02% of pre-tax profit, so the quarter's profit growth was not materially dependent on non-operating income; the tax-rate decline was also modest at 0.06 percentage points YoY.
Margin recovered from Q1 but remains below the Q3 peak
The operating margin improved from 26.70% in Q1FY27 to 28.30% in Q2FY27, after falling from 33.76% in Q3FY26 to 29.32% in Q4FY26. Sai Life's margin was 6.60 percentage points above the 21.70% median for the 83 Healthcare peers that had reported the same quarter. The latest quarter therefore shows sequential recovery, but not a return to the prior-year high in the reported trend.
Capacity spending supports management's second-half view
Management said it expects a stronger second half, citing progression in the development and commercial pipeline and the ramp-up of new capacity. The company said it invested Rs 621 cr in H1 FY27 and is on track for total capex of Rs 1,100-1,300 cr. The presentation said additional production capacity is being built at Unit 4, Bidar, while land has been acquired for a greenfield site in Choutuppal; management also said the first end-to-end integrated collaboration is expected to be fully functional in Q3.
No immediate trading response after the late filing
The results were filed after market close, so there was no trading-session response to this quarter at the time of reporting. Across the seven prior results in the history provided, the stock rose after three and fell after four, with a median absolute move of 4.45%. That record points to a mixed post-results reaction rather than a consistent direction.
Q2FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q2FY27 | Q1FY27 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹659 cr | ₹554 cr | +18.82% | +22.54% |
| Other income | ₹4 cr | ₹4 cr | +12.15% | -74.09% |
| Expenses | ₹472 cr | ₹406 cr | +16.23% | +20.57% |
| Operating profit | ₹186 cr | ₹148 cr | +25.93% | +27.82% |
| Operating margin (%) | 28.30% | 26.70% | — | — |
| Interest | ₹11 cr | ₹8 cr | +43.19% | +17.01% |
| Depreciation | ₹48 cr | ₹46 cr | +4.77% | +21.08% |
| Profit before tax | ₹131 cr | ₹98 cr | +34.00% | +17.16% |
| Tax | ₹33 cr | ₹25 cr | +33.50% | +16.84% |
| Net profit | ₹98 cr | ₹73 cr | +34.17% | +17.27% |
| EPS (₹) | ₹4.63 | ₹3.46 | +33.82% | +15.46% |
Operating margin of 28.30% compares with a Healthcare sector median of 21.70% across 83 peers that have reported Q2FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company commenced operations with its first end-to-end integrated collaboration onboarded in the previous quarter.
- One molecule was added to the late-phase pipeline and another advanced from late phase to commercial.
Guidance & outlook
- The company expects a stronger second half, supported by pipeline progression and the ramp-up of new capacity.
Planned next quarter
- The first end-to-end integrated collaboration is expected to be fully functional in Q3.
Expansion
- The company invested ₹621 crore in H1 FY27 and is on track for total capex of ₹1,100–1,300 crore.
- The company is building additional production capacity at Unit 4, Bidar and has acquired land for a greenfield site in Choutuppal.
- The company invested ₹621 crore in H1 FY27 as part of its capacity and capability expansion programme.
New initiatives
- The company is expanding its integrated outsourcing model with other large pharmaceutical companies.
What to watch
- Whether consolidated operating margin holds above 28.30% in Q3FY27.
- Whether the first end-to-end integrated collaboration becomes fully functional in Q3, as management said.
- Whether cumulative capex moves beyond the Rs 621 cr invested in H1 FY27 toward the stated Rs 1,100-1,300 cr programme.